April 12, 2019 07:58 AM EDTUpdated April 15, 04:36 AM
Bioregnum
R&D
Opinion

Go­ing vi­ral? J&J tries to spark a Twit­ter­storm for the lat­est da­ta on its HIV med

When you set out to make a block­buster, can a Twit­ter­storm help?

About 9 months af­ter the FDA OK’d J&J’s 4-in-1 HIV pill Sym­tuza …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

How blue­bird's buy­out of­fer went from $100M up­front to $29M

Roche launch­es new re­search cen­ter with Har­vard in Boston area

What the FDA, NIH hear­ings tell us about drug and health pol­i­cy un­der Trump

Bay­er eyes cap­i­tal raise as it grap­ples with Mon­san­to cas­es

At $300M Kardi­gan start­up, for­mer MyoKar­dia team un­veils its first drug, and it comes from Io­n­is

sponsored

The per­fect storm: Why every­thing is in place for 2025 to be the year of GxP AI

A service from the Financial Times